Item 1. FINANCIAL STATEMENTS
135K characters. Original on sec.gov ·
Item 1. FINANCIAL STATEMENTS
Dow Inc. and Subsidiaries
Consolidated Statements of Income
| Three Months Ended | ||||||||||||||
| In millions, except per share amounts (Unaudited) | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Net sales | $ | 9,794 | $ | 10,431 | ||||||||||
| Cost of sales | 9,154 | 9,760 | ||||||||||||
| Research and development expenses | 181 | 200 | ||||||||||||
| Selling, general and administrative expenses | 417 | 366 | ||||||||||||
| Amortization of intangibles | 46 | 76 | ||||||||||||
| Restructuring and asset related charges - net | 27 | 208 | ||||||||||||
| Equity in losses of nonconsolidated affiliates | (303) | (20) | ||||||||||||
| Sundry income (expense) - net | 121 | 13 | ||||||||||||
| Interest income | 42 | 28 | ||||||||||||
| Interest expense and amortization of debt discount | 219 | 216 | ||||||||||||
| Loss before income taxes | (390) | (374) | ||||||||||||
| Provision (credit) for income taxes | 55 | (84) | ||||||||||||
| Net loss | (445) | (290) | ||||||||||||
| Net income attributable to noncontrolling interests | 88 | 17 | ||||||||||||
| Net loss available for Dow Inc. common stockholders | $ | (533) | $ | (307) | ||||||||||
| Per common share data: | ||||||||||||||
| Loss per common share - basic | $ | (0.74) | $ | (0.44) | ||||||||||
| Loss per common share - diluted | $ | (0.74) | $ | (0.44) | ||||||||||
| Weighted-average common shares outstanding - basic | 721.2 | 706.9 | ||||||||||||
| Weighted-average common shares outstanding - diluted | 721.2 | 706.9 | ||||||||||||
| Depreciation | $ | 522 | $ | 512 | ||||||||||
| Capital expenditures | $ | 503 | $ | 685 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Net loss | $ | (445) | $ | (290) | ||||||||||
| Other comprehensive income (loss), net of tax | ||||||||||||||
| Unrealized gains on investments | 11 | 32 | ||||||||||||
| Cumulative translation adjustments | (99) | 122 | ||||||||||||
| Pension and other postretirement benefit plans | 36 | 20 | ||||||||||||
| Derivative instruments | 14 | (20) | ||||||||||||
| Total other comprehensive income (loss) | (38) | 154 | ||||||||||||
| Comprehensive loss | (483) | (136) | ||||||||||||
| Comprehensive income attributable to noncontrolling interests, net of tax | 88 | 17 | ||||||||||||
| Comprehensive loss attributable to Dow Inc. | $ | (571) | $ | (153) |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Balance Sheets
| In millions, except share amounts (Unaudited) | Mar 31, 2026 | Dec 31, 2025 | ||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents (variable interest entities restricted - 2026: $259; 2025: $31) | $ | 4,110 | $ | 3,816 | ||||
| Accounts and notes receivable: | ||||||||
| Trade (net of allowance for doubtful receivables - 2026: $63; 2025: $59) | 5,185 | 4,762 | ||||||
| Other | 2,224 | 1,876 | ||||||
| Inventories | 6,775 | 6,595 | ||||||
| Other current assets | 1,175 | 1,013 | ||||||
| Total current assets (variable interest entities restricted - 2026: $465; 2025: $228) | 19,469 | 18,062 | ||||||
| Investments | ||||||||
| Investment in nonconsolidated affiliates | 1,138 | 1,264 | ||||||
| Other investments (investments carried at fair value - 2026: $2,236; 2025: $2,212) | 3,008 | 3,017 | ||||||
| Noncurrent receivables | 444 | 309 | ||||||
| Total investments | 4,590 | 4,590 | ||||||
| Property | ||||||||
| Property | 66,017 | 65,863 | ||||||
| Less: Accumulated depreciation | 43,909 | 43,613 | ||||||
| Net property (variable interest entities restricted - 2026: $2,362; 2025: $2,385) | 22,108 | 22,250 | ||||||
| Other Assets | ||||||||
| Goodwill | 7,947 | 7,978 | ||||||
| Other intangible assets (net of accumulated amortization - 2026: $5,770; 2025: $5,727) | 1,426 | 1,486 | ||||||
| Operating lease right-of-use assets | 1,426 | 1,356 | ||||||
| Deferred income tax assets | 1,525 | 1,511 | ||||||
| Deferred charges and other assets | 1,289 | 1,305 | ||||||
| Total other assets (variable interest entities restricted - 2026: $220; 2025: $226) | 13,613 | 13,636 | ||||||
| Total Assets | $ | 59,780 | $ | 58,538 | ||||
| Liabilities and Equity | ||||||||
| Current Liabilities | ||||||||
| Notes payable | $ | 88 | $ | 90 | ||||
| Long-term debt due within one year | 793 | 222 | ||||||
| Accounts payable: | ||||||||
| Trade | 4,769 | 4,151 | ||||||
| Other | 1,392 | 1,394 | ||||||
| Operating lease liabilities - current | 348 | 340 | ||||||
| Income taxes payable | 344 | 337 | ||||||
| Accrued and other current liabilities | 2,802 | 2,649 | ||||||
| Total current liabilities (variable interest entities nonrecourse - 2026: $451; 2025: $438) | 10,536 | 9,183 | ||||||
| Long-Term Debt (variable interest entities nonrecourse - 2026: $184; 2025: $190) | 17,254 | 17,849 | ||||||
| Other Noncurrent Liabilities | ||||||||
| Deferred income tax liabilities | 348 | 364 | ||||||
| Pension and other postretirement benefits - noncurrent | 4,542 | 4,694 | ||||||
| Asbestos-related liabilities - noncurrent | 602 | 628 | ||||||
| Operating lease liabilities - noncurrent | 1,146 | 1,097 | ||||||
| Other noncurrent obligations | 8,589 | 7,201 | ||||||
| Total other noncurrent liabilities (variable interest entities nonrecourse - 2026: $350; 2025: $364) | 15,227 | 13,984 | ||||||
| Stockholders’ Equity | ||||||||
| Common stock (authorized 5,000,000,000 shares of $0.01 par value each; issued 2026: 791,896,099 shares; 2025: 790,287,565 shares) | 8 | 8 | ||||||
| Additional paid-in capital | 11,062 | 11,112 | ||||||
| Retained earnings | 15,992 | 16,781 | ||||||
| Accumulated other comprehensive loss | (7,698) | (7,660) | ||||||
| Treasury stock at cost (2026: 71,154,661 shares; 2025: 73,065,152 shares) | (4,115) | (4,233) | ||||||
| Dow Inc.’s stockholders’ equity | 15,249 | 16,008 | ||||||
| Noncontrolling interests | 1,514 | 1,514 | ||||||
| Total equity | 16,763 | 17,522 | ||||||
| Total Liabilities and Equity | $ | 59,780 | $ | 58,538 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Statements of Cash Flows
| In millions (Unaudited) | Three Months Ended | |||||||
| Mar 31, 2026 | Mar 31, 2025 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (445) | $ | (290) | ||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 719 | 714 | ||||||
| Credit for deferred income tax | (48) | (177) | ||||||
| Earnings of nonconsolidated affiliates less than dividends received | 502 | 133 | ||||||
| Net periodic pension benefit credit | (8) | (26) | ||||||
| Pension contributions | (41) | (31) | ||||||
| Net gain on sales of assets, businesses and investments | (4) | (2) | ||||||
| Restructuring and asset related charges - net | 27 | 208 | ||||||
| Other net (gain) loss | (14) | 185 | ||||||
| Changes in assets and liabilities, net of effects of acquired and divested companies: | ||||||||
| Accounts and notes receivable | (531) | (301) | ||||||
| Inventories | (180) | (221) | ||||||
| Accounts payable | 551 | 38 | ||||||
| Other assets and liabilities, net | 596 | (126) | ||||||
| Cash provided by operating activities - continuing operations | 1,124 | 104 | ||||||
| Cash provided by (used for) operating activities - discontinued operations | — | (13) | ||||||
| Cash provided by operating activities | 1,124 | 91 | ||||||
| Investing Activities | ||||||||
| Capital expenditures | (503) | (685) | ||||||
| Proceeds from incentives related to capital expenditures | 40 | — | ||||||
| Cash flow hedging related to capital expenditures | 3 | — | ||||||
| Investment in gas field developments | (21) | (30) | ||||||
| Proceeds from sales of property, businesses and consolidated companies, net of cash divested | 4 | 3 | ||||||
| Investments in and loans to nonconsolidated affiliates | — | (3) | ||||||
| Purchases of investments | (331) | (104) | ||||||
| Proceeds from sales and maturities of investments | 319 | 416 | ||||||
| Other investing activities, net | 41 | 2 | ||||||
| Cash used for investing activities | (448) | (401) | ||||||
| Financing Activities | ||||||||
| Changes in short-term notes payable | — | (1) | ||||||
| Proceeds from issuance of short-term debt greater than three months | 4 | 11 | ||||||
| Payments on short-term debt greater than three months | (4) | (6) | ||||||
| Proceeds from issuance of long-term debt | 52 | 1,013 | ||||||
| Payments on long-term debt | (46) | (957) | ||||||
| Collections on securitization programs, net of remittances | — | 15 | ||||||
| Transaction financing, debt issuance and other costs | (1) | (64) | ||||||
| Employee taxes paid for share-based payment arrangements | (14) | (16) | ||||||
| Distributions to noncontrolling interests | (59) | (22) | ||||||
| Dividends paid to stockholders | (252) | (494) | ||||||
| Cash used for financing activities | (320) | (521) | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (73) | 123 | ||||||
| Summary | ||||||||
| Increase (decrease) in cash, cash equivalents and restricted cash | 283 | (708) | ||||||
| Cash, cash equivalents and restricted cash at beginning of period | 3,952 | 2,263 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 4,235 | $ | 1,555 | ||||
| Less: Restricted cash and cash equivalents, included in "Other current assets" | 125 | 90 | ||||||
| Cash and cash equivalents at end of period | $ | 4,110 | $ | 1,465 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Statements of Equity
| Three Months Ended | ||||||||||||||
| In millions, except per share amounts (Unaudited) | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Common Stock | ||||||||||||||
| Balance at beginning and end of period | $ | 8 | $ | 8 | ||||||||||
| Additional Paid-in Capital | ||||||||||||||
| Balance at beginning of period | 11,112 | 9,203 | ||||||||||||
| Stock-based compensation | 68 | 87 | ||||||||||||
| Treasury stock issuances - compensation and benefit plans | (118) | (95) | ||||||||||||
| Balance at end of period | 11,062 | 9,195 | ||||||||||||
| Retained Earnings | ||||||||||||||
| Balance at beginning of period | 16,781 | 20,909 | ||||||||||||
| Net loss available for Dow Inc. common stockholders | (533) | (307) | ||||||||||||
| Dividends to stockholders | (252) | (494) | ||||||||||||
| Other | (4) | (7) | ||||||||||||
| Balance at end of period | 15,992 | 20,101 | ||||||||||||
| Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at beginning of period | (7,660) | (8,110) | ||||||||||||
| Other comprehensive income (loss) | (38) | 154 | ||||||||||||
| Balance at end of period | (7,698) | (7,956) | ||||||||||||
| Treasury Stock | ||||||||||||||
| Balance at beginning of period | (4,233) | (4,655) | ||||||||||||
| Treasury stock issuances - compensation and benefit plans | 118 | 95 | ||||||||||||
| Balance at end of period | (4,115) | (4,560) | ||||||||||||
| Dow Inc.'s stockholders' equity | 15,249 | 16,788 | ||||||||||||
| Noncontrolling Interests | 1,514 | 507 | ||||||||||||
| Total Equity | $ | 16,763 | $ | 17,295 | ||||||||||
| Dividends declared per share of common stock | $ | 0.35 | $ | 0.70 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Income
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Net sales | $ | 9,794 | $ | 10,431 | ||||||||||
| Cost of sales | 9,153 | 9,759 | ||||||||||||
| Research and development expenses | 181 | 200 | ||||||||||||
| Selling, general and administrative expenses | 417 | 366 | ||||||||||||
| Amortization of intangibles | 46 | 76 | ||||||||||||
| Restructuring and asset related charges - net | 27 | 208 | ||||||||||||
| Equity in losses of nonconsolidated affiliates | (303) | (20) | ||||||||||||
| Sundry income (expense) - net | 121 | 13 | ||||||||||||
| Interest income | 43 | 29 | ||||||||||||
| Interest expense and amortization of debt discount | 219 | 216 | ||||||||||||
| Loss before income taxes | (388) | (372) | ||||||||||||
| Provision (credit) for income taxes | 55 | (84) | ||||||||||||
| Net loss | (443) | (288) | ||||||||||||
| Net income attributable to noncontrolling interests | 88 | 17 | ||||||||||||
| Net loss available for The Dow Chemical Company common stockholder | $ | (531) | $ | (305) | ||||||||||
| Depreciation | $ | 522 | $ | 512 | ||||||||||
| Capital expenditures | $ | 503 | $ | 685 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Comprehensive Income
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Net loss | $ | (443) | $ | (288) | ||||||||||
| Other comprehensive income (loss), net of tax | ||||||||||||||
| Unrealized gains on investments | 11 | 32 | ||||||||||||
| Cumulative translation adjustments | (99) | 122 | ||||||||||||
| Pension and other postretirement benefit plans | 36 | 20 | ||||||||||||
| Derivative instruments | 14 | (20) | ||||||||||||
| Total other comprehensive income (loss) | (38) | 154 | ||||||||||||
| Comprehensive loss | (481) | (134) | ||||||||||||
| Comprehensive income attributable to noncontrolling interests, net of tax | 88 | 17 | ||||||||||||
| Comprehensive loss attributable to The Dow Chemical Company | $ | (569) | $ | (151) |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Balance Sheets
| In millions, except share amounts (Unaudited) | Mar 31, 2026 | Dec 31, 2025 | ||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents (variable interest entities restricted - 2026: $259; 2025: $31) | $ | 4,110 | $ | 3,816 | ||||
| Accounts and notes receivable: | ||||||||
| Trade (net of allowance for doubtful receivables - 2026: $63; 2025: $59) | 5,185 | 4,762 | ||||||
| Other | 2,224 | 1,880 | ||||||
| Inventories | 6,775 | 6,595 | ||||||
| Other current assets | 1,134 | 974 | ||||||
| Total current assets (variable interest entities restricted - 2026: $465; 2025: $228) | 19,428 | 18,027 | ||||||
| Investments | ||||||||
| Investment in nonconsolidated affiliates | 1,138 | 1,264 | ||||||
| Other investments (investments carried at fair value - 2026: $2,236; 2025: $2,212) | 3,008 | 3,017 | ||||||
| Noncurrent receivables | 439 | 303 | ||||||
| Total investments | 4,585 | 4,584 | ||||||
| Property | ||||||||
| Property | 66,017 | 65,863 | ||||||
| Less accumulated depreciation | 43,909 | 43,613 | ||||||
| Net property (variable interest entities restricted - 2026: $2,362; 2025: $2,385) | 22,108 | 22,250 | ||||||
| Other Assets | ||||||||
| Goodwill | 7,947 | 7,978 | ||||||
| Other intangible assets (net of accumulated amortization - 2026: $5,770; 2025: $5,727) | 1,426 | 1,486 | ||||||
| Operating lease right-of-use assets | 1,426 | 1,356 | ||||||
| Deferred income tax assets | 1,525 | 1,511 | ||||||
| Deferred charges and other assets | 1,289 | 1,305 | ||||||
| Total other assets (variable interest entities restricted - 2026: $220; 2025: $226) | 13,613 | 13,636 | ||||||
| Total Assets | $ | 59,734 | $ | 58,497 | ||||
| Liabilities and Equity | ||||||||
| Current Liabilities | ||||||||
| Notes payable | $ | 88 | $ | 90 | ||||
| Long-term debt due within one year | 793 | 222 | ||||||
| Accounts payable: | ||||||||
| Trade | 4,769 | 4,151 | ||||||
| Other | 1,392 | 1,394 | ||||||
| Operating lease liabilities - current | 348 | 340 | ||||||
| Income taxes payable | 344 | 337 | ||||||
| Accrued and other current liabilities | 2,686 | 2,542 | ||||||
| Total current liabilities (variable interest entities nonrecourse - 2026: $451; 2025: $438) | 10,420 | 9,076 | ||||||
| Long-Term Debt (variable interest entities nonrecourse - 2026: $184; 2025: $190) | 17,254 | 17,849 | ||||||
| Other Noncurrent Liabilities | ||||||||
| Deferred income tax liabilities | 348 | 364 | ||||||
| Pension and other postretirement benefits - noncurrent | 4,542 | 4,694 | ||||||
| Asbestos-related liabilities - noncurrent | 602 | 628 | ||||||
| Operating lease liabilities - noncurrent | 1,146 | 1,097 | ||||||
| Other noncurrent obligations | 8,457 | 7,063 | ||||||
| Total other noncurrent liabilities (variable interest entities nonrecourse - 2026: $350: 2025: $364) | 15,095 | 13,846 | ||||||
| Stockholder's Equity | ||||||||
| Common stock (authorized and issued 100 shares of $0.01 par value each) | — | — | ||||||
| Additional paid-in capital | 12,025 | 11,957 | ||||||
| Retained earnings | 11,124 | 11,915 | ||||||
| Accumulated other comprehensive loss | (7,698) | (7,660) | ||||||
| The Dow Chemical Company’s stockholder's equity | 15,451 | 16,212 | ||||||
| Noncontrolling interests | 1,514 | 1,514 | ||||||
| Total equity | 16,965 | 17,726 | ||||||
| Total Liabilities and Equity | $ | 59,734 | $ | 58,497 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Cash Flows
| In millions (Unaudited) | Three Months Ended | |||||||
| Mar 31, 2026 | Mar 31, 2025 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (443) | $ | (288) | ||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 719 | 714 | ||||||
| Credit for deferred income tax | (48) | (177) | ||||||
| Earnings of nonconsolidated affiliates less than dividends received | 502 | 133 | ||||||
| Net periodic pension benefit credit | (8) | (26) | ||||||
| Pension contributions | (41) | (31) | ||||||
| Net gain on sales of assets, businesses and investments | (4) | (2) | ||||||
| Restructuring and asset related charges - net | 27 | 208 | ||||||
| Other net (gain) loss | (13) | 185 | ||||||
| Changes in assets and liabilities, net of effects of acquired and divested companies: | ||||||||
| Accounts and notes receivable | (531) | (301) | ||||||
| Inventories | (180) | (221) | ||||||
| Accounts payable | 551 | 38 | ||||||
| Other assets and liabilities, net | 598 | (120) | ||||||
| Cash provided by operating activities | 1,129 | 112 | ||||||
| Investing Activities | ||||||||
| Capital expenditures | (503) | (685) | ||||||
| Proceeds from incentives related to capital expenditures | 40 | — | ||||||
| Cash flow hedging related to capital expenditures | 3 | — | ||||||
| Investment in gas field developments | (21) | (30) | ||||||
| Proceeds from sales of property, businesses and consolidated companies, net of cash divested | 4 | 3 | ||||||
| Investments in and loans to nonconsolidated affiliates | — | (3) | ||||||
| Purchases of investments | (331) | (104) | ||||||
| Proceeds from sales and maturities of investments | 319 | 416 | ||||||
| Other investing activities, net | 41 | 2 | ||||||
| Cash used for investing activities | (448) | (401) | ||||||
| Financing Activities | ||||||||
| Changes in short-term notes payable | — | (1) | ||||||
| Proceeds from issuance of short-term debt greater than three months | 4 | 11 | ||||||
| Payments on short-term debt greater than three months | (4) | (6) | ||||||
| Proceeds from issuance of long-term debt | 52 | 1,013 | ||||||
| Payments on long-term debt | (46) | (957) | ||||||
| Collections on securitization programs, net of remittances | — | 15 | ||||||
| Transaction financing, debt issuance and other costs | (1) | (64) | ||||||
| Employee taxes paid for share-based payment arrangements | (14) | (16) | ||||||
| Distributions to noncontrolling interests | (59) | (22) | ||||||
| Dividends paid to Dow Inc. | (257) | (515) | ||||||
| Cash used for financing activities | (325) | (542) | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (73) | 123 | ||||||
| Summary | ||||||||
| Increase (decrease) in cash, cash equivalents and restricted cash | 283 | (708) | ||||||
| Cash, cash equivalents and restricted cash at beginning of period | 3,952 | 2,263 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 4,235 | $ | 1,555 | ||||
| Less: Restricted cash and cash equivalents, included in "Other current assets" | 125 | 90 | ||||||
| Cash and cash equivalents at end of period | $ | 4,110 | $ | 1,465 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Equity
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Common Stock | ||||||||||||||
| Balance at beginning and end of period | $ | — | $ | — | ||||||||||
| Additional Paid-in Capital | ||||||||||||||
| Balance at beginning of period | 11,957 | 9,626 | ||||||||||||
| Stock-based compensation | 68 | 87 | ||||||||||||
| Balance at end of period | 12,025 | 9,713 | ||||||||||||
| Retained Earnings | ||||||||||||||
| Balance at beginning of period | 11,915 | 16,020 | ||||||||||||
| Net loss available for The Dow Chemical Company common stockholder | (531) | (305) | ||||||||||||
| Dividends to Dow Inc. | (257) | (515) | ||||||||||||
| Other | (3) | (7) | ||||||||||||
| Balance at end of period | 11,124 | 15,193 | ||||||||||||
| Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at beginning of period | (7,660) | (8,110) | ||||||||||||
| Other comprehensive income (loss) | (38) | 154 | ||||||||||||
| Balance at end of period | (7,698) | (7,956) | ||||||||||||
| The Dow Chemical Company's stockholder's equity | 15,451 | 16,950 | ||||||||||||
| Noncontrolling Interests | 1,514 | 507 | ||||||||||||
| Total Equity | $ | 16,965 | $ | 17,457 |
See Notes to the Consolidated Financial Statements.
| Dow Inc. and Subsidiaries The Dow Chemical Company and Subsidiaries (Unaudited) |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Table of Contents
NOTE 1 – CONSOLIDATED FINANCIAL STATEMENTS
Basis of Presentation
Dow Inc. is the direct parent company of The Dow Chemical Company and its consolidated subsidiaries ("TDCC" and together with Dow Inc., "Dow" or the "Company"). The unaudited interim consolidated financial statements of Dow Inc. and TDCC were prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and reflect all adjustments (including normal recurring accruals) which, in the opinion of management, are considered necessary for the fair presentation of the results for the periods presented. These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the combined Dow Inc. and TDCC Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 10-K").
As a result of the parent/subsidiary relationship between Dow Inc. and TDCC, and considering that the financial statements and disclosures of each company are substantially similar, the companies are filing a combined report for this Quarterly Report on Form 10-Q. The information reflected in the report is equally applicable to both Dow Inc. and TDCC, except where otherwise noted. Transactions between TDCC and Dow Inc. are treated as related party transactions for TDCC.
Except as otherwise indicated by the context, the term "Union Carbide" means Union Carbide Corporation, a wholly owned subsidiary of the Company. Additionally, the term "Diamond Infrastructure Solutions" means Dow InfraCo, LLC, an entity that owns and operates infrastructure assets at certain Dow locations on the U.S. Gulf Coast and became a consolidated variable interest entity on May 1, 2025. See Note 19 for additional information about Diamond Infrastructure Solutions.
NOTE 2 – RECENT ACCOUNTING GUIDANCE
Accounting Guidance Issued But Not Adopted at March 31, 2026
In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses," which is intended to improve disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. Such information should allow investors to better understand an entity's performance, assess future cash flows, and compare performance over time and with other entities. The amendments will require public business entities to disclose in the notes to the financial statements, at each interim and annual reporting period, specific information about certain costs and expenses, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each expense caption presented on the face of the income statement, and the total amount of an entity's selling expenses. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. While the adoption of ASU 2024-03 will result in enhanced disclosures, the Company does not expect it will have a material impact on its financial condition or results of operations.
In September 2025, the FASB issued ASU 2025-06, "Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software," which is intended to modernize the accounting for the costs of internal-use software given the evolution of software development to the incremental and iterative development method. The amendments remove all references to prescriptive and sequential development stages and, instead, require an entity to start capitalizing software costs when management has authorized and committed to funding the software project, and it is probable that the project will be completed and the software will be used to perform the function intended. The amendments are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period with the amendments to be applied using a prospective, modified or retrospective transition approach. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.
In December 2025, the FASB issued ASU 2025-10, "Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities," which is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The amendments are effective for public business entities for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period with the amendments to be applied using a modified prospective, modified retrospective or retrospective transition approach. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.
NOTE 3 – REVENUE
Revenue Recognition
The majority of the Company's revenue is derived from product sales. The Company's revenue related to product sales was 98 percent for the three months ended March 31, 2026 (97 percent for the three months ended March 31, 2025). The remaining sales were primarily related to the Company's insurance operations and licensing of patents and technologies. Product sales consist of sales of the Company's products to manufacturers and distributors. The Company considers order confirmations or purchase orders, which in some cases are governed by master supply agreements, to be contracts with a customer. The Company enters into licensing arrangements in which it licenses certain rights of its patents and technology to customers. Revenue from the Company’s licenses for patents and technology is derived from sales-based royalties and licensing arrangements based on billing schedules established in each contract.
Remaining Performance Obligations
Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. At March 31, 2026, the Company had unfulfilled performance obligations of $587 million ($617 million at December 31, 2025) related to the licensing of technology. The Company expects revenue to be recognized for the remaining performance obligations over the next five years.
The Company has additional remaining performance obligations for product sales that have expected durations of one year or less, product sales of materials delivered through a pipeline for which the Company has elected the "right to invoice" practical expedient, and variable consideration attributable to royalties for licenses of patents and technology. The Company has received advance payments from customers related to long-term supply agreements that are deferred and recognized over the life of the contract, with remaining contract terms that range up to 18 years. The Company will have rights to future consideration for revenue recognized when product is delivered to the customer. These payments are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the consolidated balance sheets.
Disaggregation of Revenue
The Company disaggregates its revenue from contracts with customers by operating segment and business, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows. See details in the tables below:
| Net Trade Sales by Segment and Business | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Hydrocarbons & Energy | $ | 1,306 | $ | 1,578 | ||||||||||
| Packaging and Specialty Plastics | 3,613 | 3,732 | ||||||||||||
| Packaging & Specialty Plastics | $ | 4,919 | $ | 5,310 | ||||||||||
| Industrial Solutions | $ | 968 | $ | 1,054 | ||||||||||
| Polyurethanes & Construction Chemicals | 1,653 | 1,797 | ||||||||||||
| Other | 5 | 4 | ||||||||||||
| Industrial Intermediates & Infrastructure | $ | 2,626 | $ | 2,855 | ||||||||||
| Coatings & Performance Monomers | $ | 819 | $ | 845 | ||||||||||
| Consumer Solutions | 1,261 | 1,226 | ||||||||||||
| Performance Materials & Coatings | $ | 2,080 | $ | 2,071 | ||||||||||
| Corporate | $ | 169 | $ | 195 | ||||||||||
| Total | $ | 9,794 | $ | 10,431 |
| Net Trade Sales by Geographic Region | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| U.S. & Canada | $ | 3,796 | $ | 4,227 | ||||||||||
| EMEAI 1 | 3,184 | 3,274 | ||||||||||||
| Asia Pacific | 1,738 | 1,858 | ||||||||||||
| Latin America | 1,076 | 1,072 | ||||||||||||
| Total | $ | 9,794 | $ | 10,431 |
1.Europe, Middle East, Africa and India.
Contract Assets and Liabilities
The Company receives payments from customers based upon contractual billing schedules. Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts related to the Company's contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities include payments received in advance of performance under the contract and are recognized in revenue when the performance obligations are met. "Contract liabilities - current" primarily reflects deferred revenue from prepayments from customers for product to be delivered in 12 months or less and royalty payments that are deferred and will be recognized in 12 months or less. "Contract liabilities - noncurrent" includes advance payments
that the Company has received from customers related to long-term supply agreements and royalty payments that are deferred and recognized over the life of the contract.
Revenue recognized in the first three months of 2026 from amounts included in contract liabilities at the beginning of the period was approximately $65 million (approximately $80 million in the first three months of 2025). In the first three months of 2026 and 2025, the amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional was insignificant.
The following table summarizes contract assets and liabilities at March 31, 2026 and December 31, 2025:
| Contract Assets and Liabilities | Balance Sheet Classification | Mar 31, 2026 | Dec 31, 2025 | ||||||||
| In millions | |||||||||||
| Accounts and notes receivable - trade | Accounts and notes receivable - trade | $ | 5,185 | $ | 4,762 | ||||||
| Contract liabilities - current | Accrued and other current liabilities | $ | 215 | $ | 221 | ||||||
| Contract liabilities - noncurrent | Other noncurrent obligations | $ | 1,675 | $ | 1,727 |
NOTE 4 – RESTRUCTURING AND ASSET RELATED CHARGES - NET
Charges for restructuring programs and other asset related charges, which include asset impairments, are recorded in "Restructuring and asset related charges - net" in the consolidated statements of income. For additional information on the Company's restructuring programs and other asset related charges, see Note 5 to the Consolidated Financial Statements included in the 2025 10-K.
Transform to Outperform
On January 26, 2026, the Dow Inc. Board of Directors ("Board") approved Transform to Outperform, a comprehensive set of actions designed to improve near-term Operating EBITDA by simplifying the Company's operating model, reducing its cost structure and delivering faster growth. The actions, which include a workforce reduction of approximately 4,500 roles, are expected to be substantially complete by the end of 2027. In the first quarter of 2026, the Company recorded pretax charges of $27 million for severance and related benefits costs, included in "Restructuring and asset related charges - net" in the consolidated statements of income, related to Corporate.
At March 31, 2026, $27 million of the Transform to Outperform reserve balance was included in "Accrued and other current liabilities" in the consolidated balance sheets.
2025 Restructuring Program
On January 27, 2025, the Board approved targeted actions to further achieve the Company's cost reduction initiatives in response to ongoing macroeconomic uncertainty, while reinforcing its long-term competitiveness across the economic cycle. These actions, which include a workforce reduction of approximately 1,500 roles, are expected to be substantially complete by the end of 2026.
On June 30, 2025, the Board approved restructuring actions to rationalize the Company's global asset footprint, including certain actions identified as part of the Company's previously announced strategic review of its European assets and certain corporate and other assets, and to enhance the Company's competitiveness over the economic cycle. The program includes asset write-down and write-off charges, severance and related benefit costs and other exit and disposal costs. The actions related to the shutdown of these assets are expected to be substantially complete by the end of 2027.
The following table summarizes the activities related to the 2025 Restructuring Program, including segment information:
| 2025 Restructuring Program | Severance and Related Benefit Costs | Asset Write-downs and Write-offs | Costs Associated with Exit and Disposal Activities | Total | ||||||||||
| In millions | ||||||||||||||
| Corporate | $ | 207 | $ | — | $ | — | $ | 207 | ||||||
| Total restructuring charges | $ | 207 | $ | — | $ | — | $ | 207 | ||||||
| Reserve balance at Mar 31, 2025 | $ | 207 | $ | — | $ | — | $ | 207 | ||||||
| Packaging & Specialty Plastics | $ | — | $ | 81 | $ | 77 | $ | 158 | ||||||
| Industrial Intermediates & Infrastructure | — | 63 | 26 | 89 | ||||||||||
| Performance Materials & Coatings | — | 147 | — | 147 | ||||||||||
| Corporate | 154 | 43 | — | 197 | ||||||||||
| Total restructuring charges | $ | 154 | $ | 334 | $ | 103 | $ | 591 | ||||||
| Charges against the reserve 1 | — | (334) | (103) | (437) | ||||||||||
| Cash payments | (16) | — | — | (16) | ||||||||||
| Reserve balance at Jun 30, 2025 | $ | 345 | $ | — | $ | — | $ | 345 | ||||||
| Packaging & Specialty Plastics | $ | — | $ | 3 | $ | — | $ | 3 | ||||||
| Industrial Intermediates & Infrastructure | — | 1 | 5 | 6 | ||||||||||
| Performance Materials & Coatings | — | 3 | — | 3 | ||||||||||
| Corporate | — | 1 | 10 | 11 | ||||||||||
| Total restructuring charges | $ | — | $ | 8 | $ | 15 | $ | 23 | ||||||
| Charges against the reserve 1 | — | (8) | (15) | (23) | ||||||||||
| Cash payments | (66) | — | — | (66) | ||||||||||
| Reserve balance at Sep 30, 2025 | $ | 279 | $ | — | $ | — | $ | 279 | ||||||
| Packaging & Specialty Plastics | $ | — | $ | 4 | $ | — | $ | 4 | ||||||
| Corporate | 28 | 3 | 6 | 37 | ||||||||||
| Total restructuring charges | $ | 28 | $ | 7 | $ | 6 | $ | 41 | ||||||
| Charges against the reserve 1 | — | (7) | (6) | (13) | ||||||||||
| Cash payments | (44) | — | — | (44) | ||||||||||
| Reserve balance at Dec 31, 2025 | $ | 263 | $ | — | $ | — | $ | 263 | ||||||
| Cash payments | (69) | — | — | (69) | ||||||||||
| Reserve balance at Mar 31, 2026 | $ | 194 | $ | — | $ | — | $ | 194 | ||||||
1.Costs associated with exit and disposal activities relate to asset retirement obligations and pension benefit settlement costs.
At March 31, 2026, $57 million of the restructuring reserve balance was included in "Accrued and other current liabilities" ($123 million at December 31, 2025) and $137 million was included in "Other noncurrent obligations" ($140 million at December 31, 2025) in the consolidated balance sheets.
The Company recorded pretax restructuring charges of $862 million inception-to-date under the 2025 Restructuring Program, consisting of severance and related benefit costs of $389 million, asset write-downs and write-offs of $349 million and costs associated with exit and disposal activities of $124 million.
Restructuring implementation costs, primarily decommissioning and demolition activities related to asset actions and costs associated with the Company's restructuring actions, are expected to result in additional cash expenditures of approximately $200 million. Restructuring implementation costs totaled $21 million for the three months ended March 31, 2026 (zero for the three months ended March 31, 2025).
NOTE 5 – SUPPLEMENTARY INFORMATION
| Dow Inc. Sundry Income (Expense) – Net | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Non-operating pension and other postretirement benefit plan net credits 1 | $ | 19 | $ | 38 | ||||||||||
| Foreign exchange gains 2 | 44 | 7 | ||||||||||||
| Gain related to Nova ethylene asset matter 3 | 26 | — | ||||||||||||
| Gain (loss) on sales of other assets and investments | 6 | (3) | ||||||||||||
| Loss on early extinguishment of debt | — | (60) | ||||||||||||
| Other - net | 26 | 31 | ||||||||||||
| Total sundry income (expense) – net | $ | 121 | $ | 13 |
1.See Note 15 for additional information.
2.Foreign exchange gains for the three months ended March 31, 2026 relate primarily to the Euro.
3.See Note 11 for additional information.
Sundry income (expense) - net for TDCC for the three months ended March 31, 2026 and 2025 is substantially the same as that of Dow Inc. and, therefore, Sundry income (expense) - net for TDCC is not disclosed separately.
Other Investments
The Company has investments in company-owned life insurance policies, which are recorded at their cash surrender value as of each balance sheet date, as provided below:
| Investments in Company-Owned Life Insurance | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| Gross cash value | $ | 514 | $ | 543 | ||||
| Less: Existing drawdowns 1 | 193 | 197 | ||||||
| Less: Accrued interest on drawdowns 2 | 4 | 2 | ||||||
| Investments in company-owned life insurance 3 | $ | 317 | $ | 344 |
1.Classified as "Proceeds from sales and maturities of investments" in the consolidated statements of cash flows.
2.Included in "Sundry income (expense) - net" in the consolidated statements of income.
3.Classified as "Other investments" in the consolidated balance sheets.
Supplier Finance Program
The Company facilitates a supply chain financing (“SCF”) program in the ordinary course of business in order to extend payment terms with vendors. Under the terms of this program, a vendor can voluntarily enter into an agreement with a participating financial intermediary to sell its receivables due from the Company. The vendor receives payment from the financial intermediary, and the Company pays the financial intermediary on the terms originally negotiated with the vendor, which generally range from 90 to 120 days. The vendor negotiates the terms of the agreements directly with the financial intermediary and the Company is not a party to that agreement. The financial intermediary may allow the participating vendor to utilize the Company’s creditworthiness in establishing credit spreads and associated costs, which may provide the vendor with more favorable terms than they would be able to secure on their own. The Company does not provide guarantees related to the SCF program. At March 31, 2026, outstanding obligations confirmed as valid under the SCF program were $242 million ($239 million at December 31, 2025), included in “Accounts payable – Trade” in the consolidated balance sheets.
NOTE 6 – INCOME TAXES
As the financial statements for Dow Inc. and TDCC are substantially similar, including the provision (credit) for income taxes, the following income tax discussion does not include reference to TDCC's provision (credit) for income taxes or its effective tax rate.
The Company's effective tax rate fluctuates based on, among other factors, where income is earned, the level of income relative to tax attributes and the level of equity earnings, since most earnings from the Company's equity method investments are taxed at the joint venture level.
The following table provides effective tax rate information for Dow Inc. for the three months ended March 31, 2026 and 2025:
| Effective Tax Rate Information | Three Months Ended | |||||||||||||
| Amounts in millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Loss before income taxes | $ | (390) | $ | (374) | ||||||||||
| Provision (credit) for income taxes | $ | 55 | $ | (84) | ||||||||||
| Effective tax rate | (14.1) | % | 22.5 | % |
The provision for income taxes for the three months ended March 31, 2026 was unfavorably impacted by tax expense related to the Nova Chemicals Corporation ethylene asset matter, partially offset by tax benefits related to changes in uncertain tax positions. See Note 11 for additional information.
NOTE 7 – EARNINGS PER SHARE CALCULATIONS
The following tables provide earnings per share calculations for Dow Inc. for the three months ended March 31, 2026 and 2025. Earnings per share of TDCC is not presented as this information is not required in financial statements of wholly owned subsidiaries.
| Net Loss for Earnings Per Share Calculations | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Net loss | $ | (445) | $ | (290) | ||||||||||
| Net income attributable to noncontrolling interests | 88 | 17 | ||||||||||||
| Net income attributable to participating securities 1 | 2 | 3 | ||||||||||||
| Net loss attributable to common stockholders | $ | (535) | $ | (310) |
1.Restricted stock units are considered participating securities due to the Company's practice of paying dividend equivalents on unvested shares.
| Loss Per Share - Basic and Diluted | Three Months Ended | |||||||||||||
| Dollars per share | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Loss per common share - basic | $ | (0.74) | $ | (0.44) | ||||||||||
| Loss per common share - diluted | $ | (0.74) | $ | (0.44) |
| Share Count Information | Three Months Ended | |||||||||||||
| Shares in millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Weighted-average common shares outstanding - basic | 721.2 | 706.9 | ||||||||||||
| Plus dilutive effect of equity compensation plans 1 | — | — | ||||||||||||
| Weighted-average common shares outstanding - diluted | 721.2 | 706.9 | ||||||||||||
| Stock units excluded from EPS calculations 2 | 23.2 | 14.9 |
1.The three months ended March 31, 2026 and 2025 reflect a net loss and, as such, the basic share count was used for purposes of calculating earnings per share on a diluted basis.
2.These outstanding stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.
NOTE 8 – INVENTORIES
The following table provides a breakdown of inventories:
| Inventories | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| Finished goods | $ | 3,729 | $ | 3,737 | ||||
| Work in process | 1,466 | 1,239 | ||||||
| Raw materials | 851 | 826 | ||||||
| Supplies | 1,190 | 1,181 | ||||||
| Total | $ | 7,236 | $ | 6,983 | ||||
| Adjustment of inventories to the LIFO basis | (461) | (388) | ||||||
| Total inventories | $ | 6,775 | $ | 6,595 |
NOTE 9 – NONCONSOLIDATED AFFILIATES
For additional information on the Company’s nonconsolidated affiliates, see Note 11 to the Consolidated Financial Statements included in the 2025 10-K.
The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the consolidated balance sheets are shown in the following table:
| Investments in Nonconsolidated Affiliates | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| Investment in nonconsolidated affiliates | $ | 1,138 | $ | 1,264 | ||||
| Other noncurrent obligations | (1,000) | (933) | ||||||
| Net investment in nonconsolidated affiliates | $ | 138 | $ | 331 |
At March 31, 2026, the Company had a negative investment balance in Sadara Chemical Company ("Sadara") of $895 million included in "Other noncurrent obligations" (negative $901 million at December 31, 2025) in the consolidated balance sheets. In accordance with ASC Topic 323 "Investments—Equity Method and Joint Ventures," the Company suspended recognition of its share of equity losses from Sadara in the first quarter of 2026, as the carrying value of Sadara related liabilities recorded in Dow’s consolidated balance sheets (primarily the negative investment balance and guarantee liabilities) reached the total of Dow’s existing relevant obligations and commitments. See Notes 11 and 18 for additional information.
At March 31, 2026, the Company had a negative investment balance in EQUATE Petrochemical Company K.S.C.C of $87 million included in "Other noncurrent obligations" (negative $24 million at December 31, 2025) in the consolidated balance sheets. The increase in the negative investment was driven by dividends distributed to shareholders in the first three months of 2026.
NOTE 10 – TRANSFERS OF FINANCIAL ASSETS
Accounts Receivable Programs
The Company maintains accounts receivable facilities with various financial institutions, with committed and uncommitted facilities in the United States, which are set to expire in November 2028 and committed and uncommitted facilities in Europe, which are set to expire in March 2029 (collectively, "the Programs"). Under the terms of the Programs, the Company may sell certain eligible trade accounts receivable at any point in time, up to $900 million for the U.S. committed facility and up to €400 million for the Europe committed facility. Under the terms of the Programs, the Company continues to service the receivables from the customer, but retains no interest in the receivables, and remits payment to the financial institutions. Losses on transfers of receivables were insignificant for the three months ended March 31, 2026 and 2025. The Company also provides a guarantee to the financial institutions for the creditworthiness and collection of the receivables in satisfaction of the facility. See Note 11 for additional information related to guarantees.
The Company has access to accounts receivable discounting facilities that cover certain receivables generated from sales in EMEAI, Asia Pacific and Canada (collectively, "the Facilities"). Under the terms of the Facilities, the Company retains no interest in the transferred receivables once sold and receivables are transferred with limited recourse. The Company continues to service the receivables from the customer and remits payment to the Facilities. Losses on transfers of receivables were insignificant for the three months ended March 31, 2026 and 2025.
The following table provides a summary of cash flows related to the Programs and the Facilities for the three months ended March 31, 2026 and 2025:
| Cash Flows Related to Transfers of Accounts Receivable | Three Months Ended | |||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||
| Proceeds received from new transfers | $ | — | $ | 514 | ||||
The Company did not have any balances recorded in its consolidated balance sheets related to transfers of accounts receivable at March 31, 2026 and December 31, 2025.
NOTE 11 – COMMITMENTS AND CONTINGENCIES
A summary of the Company's commitments and contingencies can be found in Note 15 to the Consolidated Financial Statements included in the 2025 10-K, which is incorporated by reference herein.
Environmental Matters
Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated, based on current law and existing technologies. At March 31, 2026, the Company had accrued obligations of $1,025 million for probable environmental remediation and restoration costs ($1,011 million at December 31, 2025), including $234 million for the remediation of Superfund sites ($221 million at December 31, 2025). This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to approximately two times that amount. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company's results of operations, financial condition and cash flows. It is the opinion of the Company’s management, however, that the possibility is remote that costs in excess of the range disclosed will have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. As new or additional information becomes available and/or certain spending trends become known, management will evaluate such information in determination of the current estimate of environmental liability.
Litigation
Asbestos-Related Matters of Union Carbide Corporation
Each quarter, Union Carbide reviews asbestos-related claims filed, settled and dismissed, as well as average settlement and resolution costs by disease category. Union Carbide also considers additional quantitative and qualitative factors such as the nature of pending claims, trial experience of Union Carbide and other asbestos defendants, current spending for defense and processing costs, significant appellate rulings and legislative developments, trends in the tort system, and their respective effects on expected future resolution costs. Union Carbide's management considers these factors in conjunction with the most recent actuarial study and determines whether a change in the estimate is warranted. Based on Union Carbide's review of 2026 activity, it was determined that no adjustment to the accrual was required at March 31, 2026.
Union Carbide’s total asbestos-related liability for pending and future claims and defense and processing costs was $684 million at March 31, 2026 ($708 million at December 31, 2025). At March 31, 2026, approximately 32 percent of the recorded claim liability related to pending claims and approximately 68 percent related to future claims.
Gain Contingency - Dow v. Nova Chemicals Corporation Ethylene Asset Matter
In 2019, the Court of King's Bench of Alberta, Canada ("Court") found Nova Chemicals Corporation ("Nova") liable for engaging in a deliberate and continuing course of conduct of conversion, breach of contract, gross negligence and willful misconduct in the operation of the companies’ jointly-owned ethylene asset in Joffre, Alberta, Canada ("Ethylene Asset"). As a result of the liability finding, which is now final and non-appealable, the Court signed a judgment ordering Nova to pay $1.43 billion Canadian dollars (equivalent to approximately $1.08 billion U.S. dollars) for damages incurred through 2012. Nova made payment in October 2019. At March 31, 2026, $201 million ($201 million at December 31, 2025) was included in "Other noncurrent obligations" in the Company's consolidated balance sheets related to the disputed portion of the 2019 damages judgment.
On June 10, 2025, the Court signed a separate judgment ordering Nova to pay an additional amount of $1.62 billion Canadian dollars (equivalent to approximately $1.2 billion U.S. dollars) for damages incurred through June 2018, which had not been previously quantified. The Court again found that Nova failed to operate the Ethylene Asset at full capacity during this time, depriving the Company’s subsidiaries of millions of pounds of ethylene. On August 11, 2025, the Court also awarded fees of approximately $100 million U.S. dollars, bringing Nova’s payment obligation to approximately $1.3 billion U.S. dollars. In March 2026, after Nova’s procedural attempt to avoid payment and enforcement measures during its pending appeal on damages was denied, Nova paid $1.4 billion Canadian dollars (equivalent to approximately $1.0 billion U.S. dollars) directly to the Company and remitted withholding tax of $452 million Canadian dollars (equivalent to $331 million U.S. dollars) to the Canada Revenue Agency ("CRA") for the tax account of one of the Company's subsidiaries. The Company has sought a refund of the entire amount remitted to the CRA, which is expected to be received in 2026.
Certain portions of the fees awarded are not appealable and are not in dispute and, in accordance with ASC 450-30 "Gain Contingencies," the Company recorded a $40 million pretax gain in the first quarter of 2026, of which $14 million was included in "Selling, general and administrative expenses" in the consolidated statements of income and $26 million was included in "Sundry income (expense) - net" in the consolidated statements of income and related to Packaging & Specialty Plastics. At March 31, 2026, the Company's consolidated balance sheets included $331 million in "Accounts and notes receivable - Other" related to the withholding tax and $119 million and $1,175 million in "Accrued and other liabilities" and "Other noncurrent obligations," respectively, related to the disputed 2025 damages judgment and related fees.
Dow has filed a similar lawsuit against Nova in the Court to recover damages due to lost ethylene volumes from the operation of the Ethylene Asset after June 2018.
Guarantees
The following table provides a summary of the final expiration, maximum future payments and recorded liability included in the consolidated balance sheets for guarantees:
| Guarantees | Mar 31, 2026 | Dec 31, 2025 | ||||||||||||||||||
| In millions | Final Expiration | Maximum Future Payments | Recorded Liability | Final Expiration | Maximum Future Payments | Recorded Liability | ||||||||||||||
| Guarantees | 2038 | $ | 1,416 | $ | 510 | 2038 | $ | 1,307 | $ | 212 |
Guarantees arise during the ordinary course of business from relationships with customers, accounts receivable facilities and nonconsolidated affiliates when the Company undertakes an obligation to guarantee the performance of others (via delivery of cash or other assets) if specified triggering events occur. With guarantees, such as commercial or financial contracts, non-performance by the guaranteed party triggers the obligation of the Company to make payments to the beneficiary of the guarantee. The majority of the Company’s guarantees relate to debt of nonconsolidated affiliates, which have expiration dates ranging from less than one year to 12 years.
The Company maintains accounts receivable facilities with various financial institutions, with committed and uncommitted facilities in the United States and in Europe. Under the terms of the Programs, the Company continues to service the receivables from the customers, but retains no interest in the receivables, and remits payment to the financial institutions. The Company also has access to accounts receivable discounting facilities, under which receivables are transferred with limited recourse. The Company’s maximum guaranteed liability for the accounts receivable facilities was zero at March 31, 2026 and December 31, 2025.
TDCC has entered into guarantee agreements related to Sadara, a nonconsolidated affiliate. Sadara reached an agreement with its lenders to re-profile its outstanding project financing debt in the first quarter of 2021. In conjunction with the debt re-profiling, TDCC currently guarantees approximately $1.2 billion of principal, and the respective interest, of Sadara’s project financing debt. Based on current market conditions and continued evaluation, the Company believes there is a more than remote probability that some future performance under the project financing guarantee may be required due to uncertainty in Sadara's cash flows. As part of the debt re-profiling, Sadara established a $500 million revolving credit facility guaranteed by Dow, which would be used to fund Dow’s pro-rata share of any potential shortfall. In 2025, Sadara drew $80 million under the revolving credit facility. The term of the revolving credit facility expires in the second quarter of 2026 and the Company believes it is probable that it will be required to perform on the existing obligation upon expiration of the revolving credit facility. See Note 9 for additional information on Dow's investment in Sadara and Note 18 for additional information on the fair value determination of the obligation.
NOTE 12 – LEASES
For additional information on the Company's leases, see Note 16 to the Consolidated Financial Statements included in the 2025 10-K.
The components of lease cost for operating and finance leases for the three months ended March 31, 2026 and 2025 were as follows:
| Lease Cost | Three Months Ended | |||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||
| Operating lease cost | $ | 106 | $ | 106 | ||||
| Finance lease cost | ||||||||
| Amortization of right-of-use assets - finance | 35 | 32 | ||||||
| Interest on lease liabilities - finance | 14 | 12 | ||||||
| Total finance lease cost | 49 | 44 | ||||||
| Short-term lease cost | 72 | 80 | ||||||
| Variable lease cost | 267 | 255 | ||||||
| Sublease income | (2) | (2) | ||||||
| Total lease cost | $ | 492 | $ | 483 |
The following table provides supplemental cash flow and other information related to leases:
| Other Lease Information | Three Months Ended | |||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
| Operating cash flows for operating leases | $ | 116 | $ | 112 | ||||
| Operating cash flows for finance leases | $ | 14 | $ | 12 | ||||
| Financing cash flows for finance leases | $ | 34 | $ | 29 | ||||
| Right-of-use assets obtained in exchange for lease obligations: | ||||||||
| Operating leases | $ | 124 | $ | 110 | ||||
| Finance leases | $ | 11 | $ | 65 |
NOTE 13 – ACCUMULATED OTHER COMPREHENSIVE LOSS
The changes in each component of accumulated other comprehensive loss ("AOCL") for the three months ended March 31, 2026 and 2025 were as follows:
| Accumulated Other Comprehensive Loss | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Unrealized Gains (Losses) on Investments | ||||||||||||||
| Beginning balance | $ | (173) | $ | (243) | ||||||||||
| Unrealized gains (losses) on investments | 11 | 40 | ||||||||||||
| Tax (expense) benefit | 3 | (7) | ||||||||||||
| Net unrealized gains (losses) on investments | 14 | 33 | ||||||||||||
| (Gains) losses reclassified from AOCL to net income (loss) 1 | (4) | (1) | ||||||||||||
| Tax expense (benefit) 2 | 1 | — | ||||||||||||
| Net (gains) losses reclassified from AOCL to net income (loss) | (3) | (1) | ||||||||||||
| Other comprehensive income (loss), net of tax | 11 | 32 | ||||||||||||
| Ending balance | $ | (162) | $ | (211) | ||||||||||
| Cumulative Translation Adjustments | ||||||||||||||
| Beginning balance | $ | (1,860) | $ | (2,063) | ||||||||||
| Gains (losses) on foreign currency translation | (76) | 126 | ||||||||||||
| Tax (expense) benefit | (15) | 3 | ||||||||||||
| Net gains (losses) on foreign currency translation | (91) | 129 | ||||||||||||
| (Gains) losses reclassified from AOCL to net income (loss) 3 | (8) | (7) | ||||||||||||
| Other comprehensive income (loss), net of tax | (99) | 122 | ||||||||||||
| Ending balance | $ | (1,959) | $ | (1,941) | ||||||||||
| Pension and Other Postretirement Benefit Plans | ||||||||||||||
| Beginning balance | $ | (5,529) | $ | (5,720) | ||||||||||
| Amortization of net loss and prior service credit reclassified from AOCL to net income (loss) 4 | 47 | 26 | ||||||||||||
| Tax expense (benefit) 2 | (11) | (6) | ||||||||||||
| Other comprehensive income (loss), net of tax | 36 | 20 | ||||||||||||
| Ending balance | $ | (5,493) | $ | (5,700) | ||||||||||
| Derivative Instruments | ||||||||||||||
| Beginning balance | $ | (98) | $ | (84) | ||||||||||
| Gains (losses) on derivative instruments | (9) | (15) | ||||||||||||
| Tax (expense) benefit | 3 | (2) | ||||||||||||
| Net gains (losses) on derivative instruments | (6) | (17) | ||||||||||||
| (Gains) losses reclassified from AOCL to net income (loss) 5 | 26 | (4) | ||||||||||||
| Tax expense (benefit) 2 | (6) | 1 | ||||||||||||
| Net (gains) losses reclassified from AOCL to net income (loss) | 20 | (3) | ||||||||||||
| Other comprehensive income (loss), net of tax | 14 | (20) | ||||||||||||
| Ending balance | $ | (84) | $ | (104) | ||||||||||
| Total AOCL ending balance | $ | (7,698) | $ | (7,956) |
1.Reclassified to "Net sales" and "Sundry income (expense) - net."
2.Reclassified to "Provision (credit) for income taxes."
3.Reclassified to "Sundry income (expense) - net."
4.These AOCL components are included in the computation of the net periodic benefit credit of the Company's defined benefit pension and other postretirement benefit plans. See Note 15 for additional information.
5.Reclassified to "Cost of sales," "Sundry income (expense) - net" and "Interest expense and amortization of debt discount."
NOTE 14 – NONCONTROLLING INTERESTS
Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the consolidated balance sheets as "Noncontrolling interests." The amount of consolidated net income attributable to the Company and the noncontrolling interests are both presented on the face of the consolidated statements of income.
The following table summarizes the activity for equity attributable to noncontrolling interests for the three months ended March 31, 2026 and 2025:
| Noncontrolling Interests | Three Months Ended | |||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||
| Balance at beginning of period | $ | 1,514 | $ | 496 | ||||
| Net income attributable to noncontrolling interests | 88 | 17 | ||||||
| Distributions to noncontrolling interests 1 | (82) | (22) | ||||||
| Cumulative translation adjustments | (6) | 16 | ||||||
| Balance at end of period | $ | 1,514 | $ | 507 |
- The three months ended March 31, 2026 includes $70 million of dividends declared but not paid, included in "Accrued and other current liabilities" in the consolidated balance sheets.
NOTE 15 – PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS
A summary of the Company's pension and other postretirement benefit plans can be found in Note 19 to the Consolidated Financial Statements included in the 2025 10-K. The following table provides the components of the Company's net periodic benefit credit for all significant plans:
| Net Periodic Benefit Credit for All Significant Plans | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| Defined Benefit Pension Plans | ||||||||||||||
| Service cost | $ | 10 | $ | 10 | ||||||||||
| Interest cost | 225 | 246 | ||||||||||||
| Expected return on plan assets | (299) | (319) | ||||||||||||
| Amortization of prior service credit | (4) | (3) | ||||||||||||
| Amortization of net loss | 60 | 40 | ||||||||||||
| Net periodic benefit credit | $ | (8) | $ | (26) | ||||||||||
| Other Postretirement Benefit Plans | ||||||||||||||
| Service cost | $ | 1 | $ | 1 | ||||||||||
| Interest cost | 8 | 9 | ||||||||||||
| Amortization of net gain | (9) | (11) | ||||||||||||
| Net periodic benefit credit | $ | — | $ | (1) |
The net periodic benefit credit, other than the service cost component, is included in "Sundry income (expense) - net" in the consolidated statements of income.
NOTE 16 – STOCK-BASED COMPENSATION
A summary of the Company's stock-based compensation plans can be found in Note 20 to the Consolidated Financial Statements included in the 2025 10-K.
Stock Incentive Plan
The Company grants stock-based compensation to employees and non-employee directors under the 2019 Stock Incentive Plan, as amended (the "2019 Plan"). The Board approved the second amendment to the 2019 Plan to increase the shares authorized for issuance on February 12, 2026, which was approved by the Company's stockholders at the 2026 Annual Meeting of Stockholders held on April 9, 2026.
Most of the Company's stock-based compensation awards are granted in the first quarter of each year. In the first quarter of 2026, Dow Inc. granted the following stock-based compensation awards to employees:
-
1.8 million stock options with a weighted-average exercise price of $32.65 per share and a weighted-average fair value of $8.00 per share;
-
3.2 million restricted stock units with a weighted-average fair value of $32.64 per share; and
-
2.4 million performance stock units with a weighted-average fair value of $35.62 per share.
Employee Stock Purchase Plan
Under the 2026 annual offering of the 2021 Employee Stock Purchase Plan (the "2021 ESPP"), most employees are eligible to purchase shares of common stock of Dow Inc. valued at up to 10 percent of their annual total base salary or wages. The number of shares purchased will be determined using the amount contributed by the employee divided by the plan price. The plan price of the stock is equal to 85 percent of the fair market value (closing price) of the common stock at March 30, 2026 (beginning) or October 2, 2026 (ending) of the offering period, whichever is lower.
In the first quarter of 2026, employees subscribed to the right to purchase approximately 2.2 million shares under the 2021 ESPP. The plan price is fixed upon the close of the offering period and will be determined in the fourth quarter of 2026. The shares will be delivered to employees in the fourth quarter of 2026.
NOTE 17 – FINANCIAL INSTRUMENTS
A summary of the Company's financial instruments, risk management policies, derivative instruments and hedging activities can be found in Note 21 to the Consolidated Financial Statements included in the 2025 10-K.
Refer to Note 18 for a summary of the fair value of financial instruments at March 31, 2026 and December 31, 2025.
Debt Securities
The Company's investments in debt securities are primarily classified as available-for-sale. The following table provides investing results from available-for-sale securities for the three months ended March 31, 2026 and 2025:
| Investing Results | Three Months Ended | |||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||
| Proceeds from sales of available-for-sale securities | $ | 213 | $ | 154 | ||||
| Gross realized gains | $ | 8 | $ | 2 | ||||
| Gross realized losses | $ | (4) | $ | (1) |
The following table summarizes contractual maturities of the Company's investments in debt securities:
| Contractual Maturities of Debt Securities at Mar 31, 2026 | Cost | Fair Value | ||||||
| In millions | ||||||||
| Within one year | $ | 81 | $ | 77 | ||||
| One to five years | 1,069 | 1,015 | ||||||
| Six to ten years | 530 | 519 | ||||||
| After ten years | 711 | 617 | ||||||
| Total | $ | 2,391 | $ | 2,228 |
Equity Securities
There were no material adjustments to the carrying value of the not readily determinable investments for impairment or observable price changes for the three months ended March 31, 2026. There was $1 million of net unrealized losses recognized in earnings on equity securities for the three months ended March 31, 2026 ($3 million of net unrealized losses for the three months ended March 31, 2025).
| Investments in Equity Securities | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| Readily determinable fair value | $ | 8 | $ | 9 | ||||
| Not readily determinable fair value | $ | 224 | $ | 225 |
Derivative Instruments
The notional amounts of the Company's derivative instruments at March 31, 2026 and December 31, 2025 were as follows:
| Notional Amounts 1 | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| Derivatives designated as hedging instruments: | ||||||||
| Interest rate contracts | $ | 950 | $ | 600 | ||||
| Foreign currency contracts | $ | 5,888 | $ | 5,114 | ||||
| Derivatives not designated as hedging instruments: | ||||||||
| Interest rate contracts | $ | 1,077 | $ | 97 | ||||
| Foreign currency contracts | $ | 18,474 | $ | 10,560 |
1.Notional amounts represent the absolute value of open derivative positions at the end of the period. Multi-leg option positions are reflected at the maximum notional position at expiration.
The notional amounts of the Company's commodity derivatives at March 31, 2026 and December 31, 2025 were as follows:
| Commodity Notionals 1 | Mar 31, 2026 | Dec 31, 2025 | Notional Volume Unit | ||||||||
| Derivatives designated as hedging instruments: | |||||||||||
| Hydrocarbon derivatives | 5.3 | 9.5 | million barrels of oil equivalent | ||||||||
| Derivatives not designated as hedging instruments: | |||||||||||
| Hydrocarbon derivatives | 0.5 | 1.4 | million barrels of oil equivalent | ||||||||
1.Notional amounts represent the net volume of open derivative positions outstanding at the end of the period.
| Maximum Maturity Dates of Derivatives Designated as Hedging Instruments | Year | ||||
| Interest rate contracts | 2027 | ||||
| Foreign currency contracts | 2027 | ||||
| Commodity contracts | 2028 |
The following table provides the fair value and balance sheet classification of derivative instruments at March 31, 2026 and December 31, 2025:
| Fair Value of Derivative Instruments | Mar 31, 2026 | Dec 31, 2025 | |||||||||||||||||||||
| In millions | Gross | Counterparty and Cash Collateral Netting 1 | Net 2 | Gross | Counterparty and Cash Collateral Netting 1 | Net 2 | |||||||||||||||||
| Asset derivatives | |||||||||||||||||||||||
| Derivatives designated as hedging instruments: | |||||||||||||||||||||||
| Interest rate contracts 3 | $ | 22 | $ | (19) | $ | 3 | $ | 9 | $ | (9) | $ | — | |||||||||||
| Interest rate contracts 4 | — | — | — | 9 | (8) | 1 | |||||||||||||||||
| Foreign currency contracts 3 | 93 | (56) | 37 | 54 | (32) | 22 | |||||||||||||||||
| Commodity contracts 3 | 771 | (716) | 55 | 171 | (147) | 24 | |||||||||||||||||
| Commodity contracts 4 | 87 | (77) | 10 | 54 | (48) | 6 | |||||||||||||||||
| Total | $ | 973 | $ | (868) | $ | 105 | $ | 297 | $ | (244) | $ | 53 | |||||||||||
| Derivatives not designated as hedging instruments: | |||||||||||||||||||||||
| Interest rate contracts 3 | $ | 1 | $ | (1) | $ | — | $ | — | $ | — | $ | — | |||||||||||
| Foreign currency contracts 3 | 146 | (50) | 96 | 44 | (36) | 8 | |||||||||||||||||
| Commodity contracts 3 | 76 | (60) | 16 | 21 | (17) | 4 | |||||||||||||||||
| Commodity contracts 4 | — | — | — | 2 | — | 2 | |||||||||||||||||
| Total | $ | 223 | $ | (111) | $ | 112 | $ | 67 | $ | (53) | $ | 14 | |||||||||||
| Total asset derivatives | $ | 1,196 | $ | (979) | $ | 217 | $ | 364 | $ | (297) | $ | 67 | |||||||||||
| Liability derivatives | |||||||||||||||||||||||
| Derivatives designated as hedging instruments: | |||||||||||||||||||||||
| Interest rate contracts 5 | $ | 24 | $ | (19) | $ | 5 | $ | 12 | $ | (9) | $ | 3 | |||||||||||
| Interest rate contracts 6 | — | — | — | 8 | (8) | — | |||||||||||||||||
| Foreign currency contracts 5 | 99 | (56) | 43 | 71 | (32) | 39 | |||||||||||||||||
| Foreign currency contracts 6 | 2 | — | 2 | — | — | — | |||||||||||||||||
| Commodity contracts 5 | 787 | (721) | 66 | 182 | (162) | 20 | |||||||||||||||||
| Commodity contracts 6 | 85 | (77) | 8 | 54 | (48) | 6 | |||||||||||||||||
| Total | $ | 997 | $ | (873) | $ | 124 | $ | 327 | $ | (259) | $ | 68 | |||||||||||
| Derivatives not designated as hedging instruments: | |||||||||||||||||||||||
| Interest rate contracts 5 | $ | 2 | $ | (1) | $ | 1 | $ | 1 | $ | — | $ | 1 | |||||||||||
| Foreign currency contracts 5 | 64 | (50) | 14 | 84 | (36) | 48 | |||||||||||||||||
| Commodity contracts 5 | 84 | (61) | 23 | 21 | (17) | 4 | |||||||||||||||||
| Commodity contracts 6 | 2 | — | 2 | 1 | — | 1 | |||||||||||||||||
| Total | $ | 152 | $ | (112) | $ | 40 | $ | 107 | $ | (53) | $ | 54 | |||||||||||
| Total liability derivatives | $ | 1,149 | $ | (985) | $ | 164 | $ | 434 | $ | (312) | $ | 122 |
1.Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.
2.Represents the net amounts included in the consolidated balance sheets.
3.Included in "Other current assets" in the consolidated balance sheets.
4.Included in "Deferred charges and other assets" in the consolidated balance sheets.
5.Included in "Accrued and other current liabilities" in the consolidated balance sheets.
6.Included in "Other noncurrent obligations" in the consolidated balance sheets.
Assets and liabilities related to forward contracts, interest rate swaps, currency swaps, options and other conditional or exchange contracts executed with the same counterparty under a master netting arrangement are netted. Collateral accounts are netted with corresponding assets or liabilities, when applicable. The Company posted cash
collateral of $18 million at March 31, 2026 ($20 million at December 31, 2025). No cash collateral was posted by counterparties with the Company at March 31, 2026 and December 31, 2025.
The following table summarizes the gain (loss) of derivative instruments in the consolidated statements of income and comprehensive income for the three months ended March 31, 2026 and 2025:
| Effect of Derivative Instruments | Gain (loss) recognized in OCI 1 | Gain (loss) recognized in income 2 | |||||||||||||||||||||||||||
| Three Months Ended | Three Months Ended | ||||||||||||||||||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2026 | Mar 31, 2025 | |||||||||||||||||||||||||
| Derivatives designated as hedging instruments: | |||||||||||||||||||||||||||||
| Fair value hedges: | |||||||||||||||||||||||||||||
| Interest rate contracts 3, 4 | $ | — | $ | — | $ | — | $ | 20 | |||||||||||||||||||||
| Excluded components 3, 5 | — | (5) | — | — | |||||||||||||||||||||||||
| Cash flow hedges: | |||||||||||||||||||||||||||||
| Interest rate contracts 3 | — | 1 | (1) | (1) | |||||||||||||||||||||||||
| Foreign currency contracts 6 | (10) | (6) | (2) | 2 | |||||||||||||||||||||||||
| Foreign currency contracts 7 | 1 | — | — | — | |||||||||||||||||||||||||
| Commodity contracts 6 | 5 | 6 | (23) | 4 | |||||||||||||||||||||||||
| Excluded components 5, 6 | (1) | — | (2) | (1) | |||||||||||||||||||||||||
| Excluded components 5, 7 | — | — | 2 | — | |||||||||||||||||||||||||
| Net foreign investment hedges: | |||||||||||||||||||||||||||||
| Foreign currency contracts | (5) | (27) | — | — | |||||||||||||||||||||||||
| Excluded components 5, 7 | 22 | 27 | 8 | 7 | |||||||||||||||||||||||||
| Total derivatives designated as hedging instruments | $ | 12 | $ | (4) | $ | (18) | $ | 31 | |||||||||||||||||||||
| Derivatives not designated as hedging instruments: | |||||||||||||||||||||||||||||
| Foreign currency contracts 7 | — | — | 94 | (56) | |||||||||||||||||||||||||
| Commodity contracts 6 | — | — | (5) | (5) | |||||||||||||||||||||||||
| Commodity contracts 7 | — | — | 1 | — | |||||||||||||||||||||||||
| Total return swap 6 | — | — | (21) | (11) | |||||||||||||||||||||||||
| Total derivatives not designated as hedging instruments | $ | — | $ | — | $ | 69 | $ | (72) | |||||||||||||||||||||
| Total derivatives | $ | 12 | $ | (4) | $ | 51 | $ | (41) |
1.OCI is defined as other comprehensive income (loss).
2.Pretax amounts.
3.Included in "Interest expense and amortization of debt discount" in the consolidated statements of income.
4.Gain (loss) recognized in income of derivatives is offset by gain (loss) recognized in income of the hedged item.
5.The excluded components are related to the time value of the derivatives designated as hedges.
6.Included in "Cost of sales" in the consolidated statements of income.
7.Included in "Sundry income (expense) - net" in the consolidated statements of income.
The following table provides the net after-tax gain (loss) expected to be reclassified from AOCL to income within the next 12 months:
| Expected Reclassifications from AOCL within the next 12 months | Mar 31, 2026 | ||||
| In millions | |||||
| Cash flow hedges: | |||||
| Interest rate contracts | $ | (3) | |||
| Commodity contracts | $ | 6 | |||
| Foreign currency contracts | $ | 5 | |||
| Excluded components | $ | (2) | |||
| Net foreign investment hedges: | |||||
| Excluded components | $ | 18 |
NOTE 18 – FAIR VALUE MEASUREMENTS
A summary of the Company's recurring and nonrecurring fair value measurements can be found in Note 22 to the Consolidated Financial Statements included in the 2025 10-K.
Fair Value Measurements on a Recurring Basis
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis:
| Fair Value Measurements on a Recurring Basis | Mar 31, 2026 | Dec 31, 2025 | ||||||||||||||||||||||||||||||
| In millions | Fair Value Level | Cost | Gain | Loss | Fair Value | Cost | Gain | Loss | Fair Value | |||||||||||||||||||||||
| Assets at fair value: | ||||||||||||||||||||||||||||||||
| Cash equivalents: | ||||||||||||||||||||||||||||||||
| Held-to-maturity securities 1 | Level 2 | $ | 160 | $ | — | $ | — | $ | 160 | $ | 624 | $ | — | $ | — | $ | 624 | |||||||||||||||
| Money market funds | Level 2 | 1,460 | — | — | 1,460 | 923 | — | — | 923 | |||||||||||||||||||||||
| Marketable securities 2 | Level 2 | 442 | — | (32) | 410 | 446 | — | (61) | 385 | |||||||||||||||||||||||
| Other investments: | ||||||||||||||||||||||||||||||||
| Debt securities: 3 | ||||||||||||||||||||||||||||||||
| Government debt 4 | Level 2 | 1,233 | 14 | (89) | 1,158 | 1,221 | 24 | (83) | 1,162 | |||||||||||||||||||||||
| Corporate bonds | Level 1 | 14 | — | (1) | 13 | 14 | — | (1) | 13 | |||||||||||||||||||||||
| Corporate bonds | Level 2 | 944 | 4 | (66) | 882 | 910 | 10 | (57) | 863 | |||||||||||||||||||||||
| Corporate bonds | Level 3 | 200 | — | (25) | 175 | 200 | — | (35) | 165 | |||||||||||||||||||||||
| Equity securities 3, 5 | Level 1 | 5 | 4 | (1) | 8 | 4 | 5 | — | 9 | |||||||||||||||||||||||
| Derivatives relating to: 6 | ||||||||||||||||||||||||||||||||
| Interest rates | Level 2 | — | 23 | — | 23 | — | 18 | — | 18 | |||||||||||||||||||||||
| Foreign currency | Level 2 | — | 239 | — | 239 | — | 98 | — | 98 | |||||||||||||||||||||||
| Commodities | Level 1 | — | 7 | — | 7 | — | 2 | — | 2 | |||||||||||||||||||||||
| Commodities | Level 2 | — | 927 | — | 927 | — | 246 | — | 246 | |||||||||||||||||||||||
| Total assets at fair value | $ | 5,462 | $ | 4,508 | ||||||||||||||||||||||||||||
| Liabilities at fair value: | ||||||||||||||||||||||||||||||||
| Long-term debt including debt due within one year 7 | Level 2 | $ | (18,047) | $ | 1,883 | $ | (285) | $ | (16,449) | $ | (18,071) | $ | 1,746 | $ | (342) | $ | (16,667) | |||||||||||||||
| Guarantee liability 8 | Level 3 | (510) | (212) | |||||||||||||||||||||||||||||
| Derivatives relating to: 6 | ||||||||||||||||||||||||||||||||
| Interest rates | Level 2 | — | — | (26) | (26) | — | — | (21) | (21) | |||||||||||||||||||||||
| Foreign currency | Level 2 | — | — | (165) | (165) | — | — | (155) | (155) | |||||||||||||||||||||||
| Commodities | Level 1 | — | — | (9) | (9) | — | — | (15) | (15) | |||||||||||||||||||||||
| Commodities | Level 2 | — | — | (949) | (949) | — | — | (243) | (243) | |||||||||||||||||||||||
| Total liabilities at fair value | $ | (18,108) | $ | (17,313) |
1.The Company's held-to-maturity securities primarily relate to treasury bills and time deposits. At March 31, 2026, $94 million is included in "Cash and cash equivalents" ($555 million at December 31, 2025) and $66 million is included in "Other current assets" ($69 million at December 31, 2025) in the consolidated balance sheets.
2.The Company’s investments in marketable securities are included in “Other current assets” in the consolidated balance sheets.
3.The Company’s investments in debt securities, which are primarily available-for-sale, and equity securities are included in “Other investments” in the consolidated balance sheets.
4.U.S. Treasury obligations, U.S. agency obligations, U.S. agency mortgage-backed securities and other municipalities’ obligations.
5.Equity securities with a readily determinable fair value.
6.See Note 17 for classification of derivatives in the consolidated balance sheets.
7.Cost includes fair value hedge adjustment gains of $27 million at March 31, 2026 and December 31, 2025 on $5,888 million of debt at March 31, 2026 and $5,538 million at December 31, 2025.
8.Estimated liability for TDCC's guarantee of Sadara's debt, of which $430 million is included in "Other noncurrent obligations" ($132 million at December 31, 2025) and $80 million is included in "Accrued and other current liabilities" ($80 million at December 31, 2025) in the consolidated balance sheets.
Cost approximates fair value for all other financial instruments.
For equity securities calculated at net asset value per share (or its equivalent), the Company had $109 million in private market securities and $12 million in real estate at March 31, 2026 ($109 million in private market securities and $13 million in real estate at December 31, 2025). There are no redemption restrictions and the unfunded commitments on these investments were $95 million at March 31, 2026 and $65 million at December 31, 2025.
For assets classified as Level 3 measurements, fair value is based on significant unobservable inputs including assumptions where there is little, if any, market activity. The level 3 asset values represent the fair value of an investment in a corporate bond, accounted for as a debt security.
For liabilities classified as Level 3 measurements, fair value is based on significant unobservable inputs including assumptions where there is little, if any, market activity. The fair value of the Company’s accrued liability related to the guarantee of Sadara’s project financing debt is in proportion to the Company’s 35 percent ownership interest in Sadara. The estimated fair value of the project financing debt guarantee was calculated using a "with" and "without" method. The fair value of the debt was calculated "with" the guarantee less the fair value of the debt "without" the guarantee. The "with" and "without" values were calculated using a discounted cash flow method based on contractual cash flows as well as projected prepayments made on the debt by Sadara. During the three months ended March 31, 2026, the fair value of the project financing debt guarantee liability increased by $298 million, which was included in “Equity in losses of nonconsolidated affiliates” in the consolidated statements of income. The increase in fair value was primarily attributable to adverse business conditions impacting Sadara’s operations, including the ongoing conflicts in the Middle East. The Company has also guaranteed Sadara's obligation related to its $500 million revolving credit facility. In 2025, Sadara drew $80 million from this facility. The estimated fair value of the revolving credit facility guarantee was calculated based on a discounted cash flow analysis of the Company's expected obligation to make future payments on behalf of Sadara in the second quarter of 2026. See Note 11 for further information on guarantees classified as Level 3 measurements.
NOTE 19 – VARIABLE INTEREST ENTITIES
A summary of the Company's variable interest entities ("VIEs") not discussed below can be found in Note 23 to the Consolidated Financial Statements included in the 2025 10-K.
Assets and Liabilities of Consolidated VIEs
The Company's consolidated financial statements include the assets, liabilities and results of operations of VIEs for which the Company is the primary beneficiary. The other equity holders’ interests are included in “Net income attributable to noncontrolling interests” in the consolidated statements of income and "Noncontrolling interests" in the consolidated balance sheets.
Infrastructure Entity
The Company has variable interests in Diamond Infrastructure Solutions, an entity that owns and operates infrastructure assets at certain Dow locations on the U.S Gulf Coast. The Company's variable interests relate to its membership interest and the service contracts between Diamond Infrastructure Solutions and Dow, under which a majority of the infrastructure services are provided to Dow using pass-through and cost-plus pricing. Diamond Infrastructure Solutions became a variable interest entity effective with the noncontrolling interest transaction on May 1, 2025. Dow is deemed the primary beneficiary as a result of decision rights held as the majority member.
The following table summarizes the carrying amounts of Diamond Infrastructure Solutions' assets and liabilities included in the Company’s consolidated balance sheets at March 31, 2026 and December 31, 2025. Amounts presented are adjusted for intercompany eliminations.
| Assets and Liabilities of Diamond Infrastructure Solutions | Mar 31, 2026 | Dec 31, 2025 | |||||||||
| In millions | |||||||||||
| Cash and cash equivalents | $ | 216 | $ | — | |||||||
| Other current assets | 172 | 161 | |||||||||
| Net property | 2,257 | 2,273 | |||||||||
| Other noncurrent assets | 205 | 211 | |||||||||
| Total assets 1 | $ | 2,850 | $ | 2,645 | |||||||
| Current liabilities | $ | 430 | $ | 414 | |||||||
| Long-term debt | 184 | 190 | |||||||||
| Other noncurrent obligations | 337 | 351 | |||||||||
| Total liabilities 2 | $ | 951 | $ | 955 |
1.All assets were restricted at March 31, 2026 and December 31, 2025. Cash and cash equivalents held by the consolidated VIE is available for use in the ordinary course of business of the VIE entity and is not classified as restricted cash in the consolidated balance sheets.
2.All liabilities were nonrecourse at March 31, 2026 and December 31, 2025.
Other Consolidated VIEs
In addition, the Company holds variable interests and is the primary beneficiary of other joint ventures and entities. The following table summarizes the carrying amounts of other entities' assets and liabilities included in the Company’s consolidated balance sheets at March 31, 2026 and December 31, 2025:
| Assets and Liabilities of Other Consolidated VIEs | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| Cash and cash equivalents | $ | 43 | $ | 31 | ||||
| Other current assets | 163 | 253 | ||||||
| Net property | 105 | 112 | ||||||
| Other noncurrent assets | 15 | 15 | ||||||
| Total assets 1 | $ | 326 | $ | 411 | ||||
| Current liabilities | $ | 21 | $ | 24 | ||||
| Other noncurrent obligations | 13 | 13 | ||||||
| Total liabilities 2 | $ | 34 | $ | 37 |
1.Restricted assets totaled $197 million and $194 million at March 31, 2026 and December 31, 2025, respectively. Cash and cash equivalents held by the consolidated VIEs is available for use in the ordinary course of business of the respective VIE entities and is not classified as restricted cash in the consolidated balance sheets.
2.All liabilities were nonrecourse at March 31, 2026 and December 31, 2025.
Amounts presented in the consolidated balance sheets and the table above as restricted assets or nonrecourse obligations relating to consolidated VIEs are adjusted for intercompany eliminations at March 31, 2026 and December 31, 2025.
NOTE 20 – SEGMENTS AND GEOGRAPHIC REGIONS
Sales to external customers, which are attributed to geographic regions based on customer location, were as follows:
| Sales to External Customers by Geographic Region | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||||||||
| United States | $ | 3,513 | $ | 3,946 | ||||||||||
| EMEAI | 3,184 | 3,274 | ||||||||||||
| Rest of World | 3,097 | 3,211 | ||||||||||||
| Total | $ | 9,794 | $ | 10,431 |
Long-lived assets, which are attributed to geographic regions based on asset location, were as follows:
| Long-Lived Assets by Geographic Region | Mar 31, 2026 | Dec 31, 2025 | ||||||
| In millions | ||||||||
| United States | $ | 14,560 | $ | 14,804 | ||||
| EMEAI | 2,652 | 2,750 | ||||||
| Rest of World | 4,896 | 4,696 | ||||||
| Total | $ | 22,108 | $ | 22,250 |
Dow’s measure of profit/loss for segment reporting purposes is Operating EBIT as this is the manner in which the chief executive officer, chief operating officer, chief financial officer, general counsel and corporate secretary, and senior vice president of corporate development, together the "executive committee" and CODM, assesses performance and allocates resources. The CODM compares quarterly results to both the year-ago and sequential periods to assess performance and allocate resources to each segment. The Company defines Operating EBIT as earnings (i.e., "Loss before income taxes") before interest, excluding the impact of significant items. Operating EBIT by segment includes all operating items relating to the businesses; items that principally apply to Dow as a whole are assigned to Corporate.
| Segment Operating EBIT 1 | Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Materials & Coatings | Operating Segment Total | ||||||||||
| In millions | ||||||||||||||
| Three months ended Mar 31, 2026 | ||||||||||||||
| Net sales | $ | 4,919 | $ | 2,626 | $ | 2,080 | $ | 9,625 | ||||||
| Cost of sales | 4,536 | 2,609 | 1,793 | 8,938 | ||||||||||
| SARD 2 | 212 | 129 | 164 | 505 | ||||||||||
| Equity in earnings (losses) of nonconsolidated affiliates | 18 | (31) | 1 | (12) | ||||||||||
| Other segment income (expense) items 3 | 19 | 25 | (7) | 37 | ||||||||||
| Segment Operating EBIT 4 | $ | 208 | $ | (118) | $ | 117 | $ | 207 | ||||||
| Three months ended Mar 31, 2025 | ||||||||||||||
| Net sales | $ | 5,310 | $ | 2,855 | $ | 2,071 | $ | 10,236 | ||||||
| Cost of sales | 4,765 | 2,822 | 1,845 | 9,432 | ||||||||||
| SARD 2 | 240 | 127 | 151 | 518 | ||||||||||
| Equity in earnings (losses) of nonconsolidated affiliates | 39 | (58) | — | (19) | ||||||||||
| Other segment income (expense) items 3 | (2) | 24 | (26) | (4) | ||||||||||
| Segment Operating EBIT 4 | $ | 342 | $ | (128) | $ | 49 | $ | 263 | ||||||
1.Significant expense categories are presented on an operating basis, net of the impact of significant items.
2.SARD includes selling, general and administrative and research and development expenses.
3.Other segment income (expense) items includes amortization of intangibles and sundry income (expense) - net.
4.Segment Operating EBIT for TDCC for the three months ended March 31, 2026 and 2025 is substantially the same as that of Dow Inc. and therefore is not disclosed separately in the table above. A reconciliation of "Segment Operating EBIT" to "Loss before income taxes" is provided in the following table.
| Reconciliation of "Segment Operating EBIT" to "Loss Before Income Taxes" | Three Months Ended | |||||||
| In millions | Mar 31, 2026 | Mar 31, 2025 | ||||||
| Segment Operating EBIT | $ | 207 | $ | 263 | ||||
| + Corporate Operating EBIT | (53) | (33) | ||||||
| + Interest income | 42 | 28 | ||||||
| - Interest expense and amortization of debt discount | 219 | 216 | ||||||
| + Significant items | (367) | (416) | ||||||
| Loss before income taxes | $ | (390) | $ | (374) |
| Other Segment Information | Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Materials & Coatings | Operating Segment Total | Corp. 1 | Total | ||||||||||||||
| In millions | ||||||||||||||||||||
| Three months ended Mar 31, 2026 | ||||||||||||||||||||
| Net sales | $ | 4,919 | $ | 2,626 | $ | 2,080 | $ | 9,625 | $ | 169 | $ | 9,794 | ||||||||
| Depreciation and amortization | $ | 382 | $ | 148 | $ | 181 | $ | 711 | $ | 8 | $ | 719 | ||||||||
| Capital expenditures | $ | 418 | $ | 40 | $ | 45 | $ | 503 | $ | — | $ | 503 | ||||||||
| Operating EBIT | $ | 208 | $ | (118) | $ | 117 | $ | 207 | $ | (53) | $ | 154 | ||||||||
| Three months ended Mar 31, 2025 | ||||||||||||||||||||
| Net sales | $ | 5,310 | $ | 2,855 | $ | 2,071 | $ | 10,236 | $ | 195 | $ | 10,431 | ||||||||
| Depreciation and amortization | $ | 360 | $ | 146 | $ | 200 | $ | 706 | $ | 8 | $ | 714 | ||||||||
| Capital expenditures | $ | 515 | $ | 129 | $ | 41 | $ | 685 | $ | — | $ | 685 | ||||||||
| Operating EBIT | $ | 342 | $ | (128) | $ | 49 | $ | 263 | $ | (33) | $ | 230 | ||||||||
1.Corporate contains the reconciliation between the totals for the operating segments and the Company's totals. Net sales for Corporate are primarily related to insurance operations. Corporate expenses are primarily related to insurance operations, salaries and wages and non-business aligned environmental and legal costs.
| Segment Asset Information | Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Materials & Coatings | Operating Segment Total | Corp. | Total | ||||||||||||||
| In millions | ||||||||||||||||||||
| Mar 31, 2026 | ||||||||||||||||||||
| Total assets | $ | 31,491 | $ | 10,829 | $ | 11,902 | $ | 54,222 | $ | 5,558 | $ | 59,780 | ||||||||
| Investments in nonconsolidated affiliates 1 | $ | 666 | $ | 301 | $ | 134 | $ | 1,101 | $ | 37 | $ | 1,138 | ||||||||
| Dec 31, 2025 | ||||||||||||||||||||
| Total assets | $ | 30,251 | $ | 11,263 | $ | 11,407 | $ | 52,921 | $ | 5,617 | $ | 58,538 | ||||||||
| Investments in nonconsolidated affiliates 1 | $ | 677 | $ | 413 | $ | 137 | $ | 1,227 | $ | 37 | $ | 1,264 |
1.See Note 9 for additional information regarding the Company's investments in nonconsolidated affiliates.
The following tables summarize the pretax impact of significant items by segment excluded from Operating EBIT:
| Significant Items by Segment | Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Materials & Coatings | Operating Segment Total | Corp. | Total | |||||||||||||||||||||||||||||
| In millions | |||||||||||||||||||||||||||||||||||
| Three months ended Mar 31, 2026 | |||||||||||||||||||||||||||||||||||
| Transform to Outperform 1 | $ | — | $ | — | $ | — | $ | — | $ | (80) | $ | (80) | |||||||||||||||||||||||
| 2025 Restructuring implementation costs 2 | (1) | — | — | (1) | (20) | (21) | |||||||||||||||||||||||||||||
| Sadara guarantee liability adjustment 3 | (81) | (211) | — | (292) | — | (292) | |||||||||||||||||||||||||||||
| Litigation related charges, awards and adjustments 4 | 26 | — | — | 26 | — | 26 | |||||||||||||||||||||||||||||
| Total significant items by segment | $ | (56) | $ | (211) | $ | — | $ | (267) | $ | (100) | $ | (367) | |||||||||||||||||||||||
1.Includes costs to achieve of $53 million and severance and related benefit costs of $27 million associated with Transform to Outperform. See Note 4 for additional information related to severance and related benefit costs.
2.Implementation costs associated with the Company's 2025 Restructuring Program. See Note 4 for additional information.
3.Loss due to change in fair value of the estimated liability associated with the Company's guarantee of Sadara's project financing debt. See Notes 9, 11 and 18 for additional information.
4.Related to a gain associated with a legal matter with Nova. See Note 11 for additional information.
| Significant Items by Segment | Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Materials & Coatings | Operating Segment Total | Corp. | Total | ||||||||||||||
| In millions | ||||||||||||||||||||
| Three months ended Mar 31, 2025 | ||||||||||||||||||||
| Restructuring, implementation and efficiency costs, and asset related charges - net 1 | $ | — | $ | (1) | $ | — | $ | (1) | $ | (50) | $ | (51) | ||||||||
| 2025 Restructuring Program severance and related benefit costs 2 | — | — | — | — | (207) | (207) | ||||||||||||||
| Loss on early extinguishment of debt 3 | — | — | — | — | (60) | (60) | ||||||||||||||
| Indemnification and other transactions related costs 4 | — | — | — | — | (98) | (98) | ||||||||||||||
| Total significant items by segment | $ | — | $ | (1) | $ | — | $ | (1) | $ | (415) | $ | (416) | ||||||||
1.Includes restructuring charges and implementation and efficiency costs associated with the Company's 2023 Restructuring Program. Also includes impairment charges related to the write-down of certain manufacturing assets, partially offset by an asset related credit adjustment. See Note 4 for additional information.
2.Severance and related benefit costs associated with the Company's 2025 Restructuring Program. See Note 4 for additional information.
3.The Company retired outstanding long-term debt resulting in a loss on early extinguishment.
4.Includes charges related to an arbitration settlement agreement for historical product claims from a divested business.
Previous: Cover and table of contents · Next: Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.